|
Neuroinflammation in Alzheimer's Disease: controversies and new insights| old_uid | 11893 |
|---|
| title | Neuroinflammation in Alzheimer's Disease: controversies and new insights |
|---|
| start_date | 2012/11/30 |
|---|
| schedule | 11h30 |
|---|
| online | no |
|---|
| location_info | salle de conférence CGFB |
|---|
| details | Une invitation de Thiérry Amédée. |
|---|
| summary | Conflicting results have been reported in the literature concerning the role of neuroinflammation in Alzheimer's disease. On one hand, prospective studies with anti-inflammatory drugs in patients with Alzheimer's disease have shown no effect, or even a worsening of the pathology. Based on those results, it appears that blocking inflammation is not a suitable therapeutic approach to cure Alzheimer's disease. On the other hand, epidemiological data demonstrated that life-long users of nonsteroidal anti-inflammatory drugs develop the disease with reduced frequency. Such evidence would rather suggest that the inhibition of inflammation in early stages is protective against the onset of the pathology later in life. The contradictory reports might be consistent with a biphasic involvement of inflammation in Alzheimer's disease: a latent, pre-clinical inflammatory process, which would facilitate the disease progression, followed by a later, plaque-associated inflammation, which would be mostly beneficial. This lecture will offer a critical overview of the clinical and preclinical data available on the role of neuroinflammation in Alzheimer's disease. The evidence supporting a biphasic role of inflammation in the progression of the pathology will be discussed. In particular, I will be presenting preliminary results generated at McGill University suggesting a pivotal role of microglial activation in pre-plaque stages of the disease. |
|---|
| responsibles | Deris |
|---|
| |
|